

September 18, 2014



# Amedica Corporation Builds on Success of Valeo II(TM) Silicon Nitride Interbody Spinal Fusion Devices

## Redesigned Transforaminal Lumbar Device Provides Amedica With Broader Interbody Fusion Device Market Opportunities

SALT LAKE CITY, Sept. 18, 2014 (GLOBE NEWSWIRE) -- Amedica Corporation (Nasdaq:AMDA), a commercial biomaterial company focused on silicon nitride ceramics as a material platform to develop, manufacture and sell novel medical devices, is pleased to announce the release of its second generation silicon nitride transforaminal lumbar (TL) interbody fusion device. The Valeo II™ TL interbody fusion device includes optimized instrumentation to improve patient safety and surgeon ease of use, while maximizing central cavity space for autograft packing to facilitate fusion through the implant.

The Valeo II™ TL is made of a micro composite silicon nitride biomaterial, which offers a superior environment for bone growth and osteointegration, when compared to competitive PEEK and titanium offerings. [Valeo II™ TL](#) silicon nitride interbody fusion devices also contain anti-infective properties and are semi-radiolucent with clearly visible boundaries in x-rays and produce no artifacts under MRI or CT scans. The combination of these properties is found only in Amedica's silicon nitride biomaterial technology.

"With more than 20,000 implants to-date of our Valeo products, we're proud to further expand our line of silicon nitride spinal interbody offerings," said Eric Olson, CEO and President of Amedica. "This second generation TL device, in tandem with our anterior, posterior and oblique lumbar second generation silicon nitride interbody devices, greatly strengthens our ability to capture additional share within the \$1.4 billion spinal interbody fusion device market. We remain dedicated to bringing new and innovative solutions to the market that we believe offer distinct benefits to improve the efficacy of spinal fusion procedures, resulting in enhanced patient care."

The Valeo II™ TL is indicated for intervertebral body fusion of the spine in skeletally mature patients and is designed for use with autograft to facilitate fusion. Additional information about Amedica's complete line of products can be found at [www.amedica.com](http://www.amedica.com).

### About Amedica Corporation

Amedica is a company focused on the development and application of medical-grade silicon nitride ceramics. Amedica markets spinal fusion products and is developing a new generation of orthopaedic bearings for hip and knee arthroplasty. Amedica operates an ISO 13485 certified manufacturing facility and its spine products are FDA cleared, CE marked, and currently marketed in the U.S. and select markets in Europe and South America.

The Company's web site for news releases and other information is [www.amedica.com](http://www.amedica.com).

## **Forward-Looking Statements**

This press release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief or current expectations of Amedica and members of its management team with respect to Amedica's future business operations as well as the assumptions upon which such statements are based. Forward-looking statements include specifically, but are not limited to, Amedica's market opportunities, growth, future products, market acceptance of its products, sales and financial results and such statements are subject to risks and uncertainties such as the timing and success of new product introductions, physician acceptance, endorsement, and use of Amedica's products, regulatory matters, competitor activities, changes in and adoption of reimbursement rates, potential product recalls, effects of global economic conditions and changes in foreign currency exchange rates. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found in Amedica's Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 31, 2014, and in Amedica's other filings with the SEC. Amedica disclaims any obligation to update any forward-looking statements.

CONTACT: Mike Houston  
Director of Investor Relations  
801-839-3534  
mhouston@amedica.com

Source: Amedica Corporation